Distinguished Professor and Doctoral Supervisor at Shanghai Jiao Tong University, National-level High-level Talent, Chief Scientist of the National Key R&D Program, Shanghai Science and Technology Elite, and Shanghai Outstanding Academic Leader. Former Deputy Director of the Department of Pharmacy at Changzheng Hospital; currently Director of the Marine Drug Fusion Innovation Center at Shanghai Jiao Tong University, Dean of the School of Clinical Pharmacy at Shanghai Jiao Tong University School of Medicine, PI of the State Key Laboratory of Microbial Metabolism, and Director of the Department of Pharmacy at Renji Hospital. Recipient of the military outstanding professional and technical personnel post allowance, and awarded a personal third-class merit once. Concurrently serves as Chairman and Chairman of the Standing Committee of the Marine Professional Branch of the Chinese Society of Biochemistry and Molecular Biology, Standing Director of the 13th Council of the Chinese Society of Biochemistry and Molecular Biology, Vice Chairman of the Marine Biological Resources Professional Committee of the Chinese Society for Oceanology, Vice Chairman of the Marine Drug Professional Committee of the Chinese Pharmaceutical Association, Vice Chairman of the Diabetes Branch of the Lean Diagnosis and Treatment Expert Committee of the National Telemedicine and Internet Medical Center, Vice Chairman of the Cardiovascular Pharmacy Branch of the Chinese Association of Cardiothoracic Vascular Anesthesia, Vice Chairman of the Hospital Pharmacy Professional Committee of the Shanghai Pharmaceutical Association, and Standing Director of the Shanghai Pharmaceutical Association. Professor Lin Houwen has long been dedicated to evidence-based and precision medication research for major chronic diseases: (1) constructing a rational medication system of "scientific evidence-based - real-world evidence generation - standardized evidence application"; (2) establishing a precision medication system of "point-of-care testing - refined subtyping - targeted intervention"; (3) creating a new drug clinical positioning technology system of "evidence-based guidance - pharmacological exploration - clinical validation," forming a "precision medication and new drug clinical positioning" technology system for major chronic diseases such as rheumatic immunology, oncology, and cardiovascular diseases, improving evidence-based medication evidence for chronic diseases such as rheumatism and oncology, pioneering a research-oriented clinical pharmacist training model, leading the establishment of China's first Yangtze River Delta Anticoagulation Pharmacist Alliance, building an intelligent chronic disease medication management system, successfully applied in 108 medical institutions nationwide, benefiting more than 50,000 patients. Established a new paradigm of clinical value-oriented drug research and development, conducting full-chain drug innovation from efficient discovery of active molecules to druggability evaluation, developing 3 candidate drugs with independent intellectual property rights, authorizing 34 drug invention patents and 2 PCT patents, and publishing more than 200 papers in journals such as EClinicalMedicine and Angewandte Chemie, International Edition. Presided over 18 national-level research projects including the Ministry of Science and Technology National Key R&D Program and Key Projects of the National Natural Science Foundation of China. As first completer, received 4 awards including the First Prize for Scientific and Technological Progress from the Ministry of Education, the First Prize for Scientific and Technological Progress from the Ministry of Natural Resources, and the First Prize for Marine Science and Technology Progress, achieving 10 million yuan in transformation of scientific and technological achievements, and was awarded honors including the 17th Shanghai Science and Technology Elite, the 8th Top Ten Medical Promotion Experts, and Outstanding Pharmacist of the Chinese Pharmaceutical Association, leading the discipline to rank first in discipline competitiveness among Shanghai municipal hospitals, and receiving one Gold Award and one Silver Award in Discipline Management at the China Hospital Management Awards. As Party Branch Secretary, led the collective to receive multiple honors including the National Public Hospital Clinical Department Benchmark Party Branch (2023), the Shanghai Public Hospital Party Building Model Branch (2022), and the Two-Star National Youth Civilization Award (2023).